Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01284192 · ClinicalTrials.gov registry record · Phase 1
Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)
A Phase 1 study of Solid Tumor and B-cell Lymphoma, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
- 6
- Study locations
NCT01284192: Completed Phase 1 study of Solid Tumor and B-cell Lymphoma, sponsored by Astellas Pharma.
NCT01284192 is a Phase 1 study of Solid Tumor and B-cell Lymphoma that has completed, run by Astellas Pharma. The registered enrollment target is 46 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (79% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01284192, a Phase 1 study of Solid Tumor and B-cell Lymphoma, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
- 6
- Study locations
Study Summary
This study is to evaluate the safety and anti-tumor activity of ASP3026 in patients with advanced malignancies (solid tumors and B-cell lymphoma).
Conditions Studied
Interventions
- DRUG ASP3026
Study Locations (6)
California
- Site US160 - Orange
- Site US184 - Sacramento
Texas
- Site US2492 - Houston
- Site US1905 - San Antonio
Illinois
- Site US11 - Chicago
Michigan
- Site US2688 - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2010-12 |
| Est. Completion | 2016-03 |
| Phase | Phase 1 |
What the finished NCT01284192 record still lists
NCT01284192 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (79% lower).
The record links to 5 conditions, with Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which ASP3026 is the first listed.
NCT01284192 lists 6 locations in 4 states (California, Texas, Illinois).
Frequently Asked Questions
What is clinical trial NCT01284192 about?
NCT01284192 is a clinical study titled "Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)". This study is to evaluate the safety and anti-tumor activity of ASP3026 in patients with advanced malignancies (solid tumors and B-cell lymphoma).
What is the current status of trial NCT01284192?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2010-12. Estimated completion is 2016-03.
What conditions does trial NCT01284192 study?
This clinical trial studies the following conditions: Solid Tumor, B-cell Lymphoma, Advanced Malignancies, Positive for Anaplastic Lymphoma Kinase, Positive for Proto-Oncogene Tyrosine-Protein Kinase ROS.
What interventions are being tested in trial NCT01284192?
The interventions under investigation include: ASP3026 (DRUG).
Who is sponsoring clinical trial NCT01284192?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01284192 being conducted?
This trial has 6 study locations across California, Illinois, Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01284192's enrollment target sits among peer trials
46 131st of 196 higher than 65 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia